Home › Compare › MAOIF vs ABBV
MAOIF yields 6.29% · ABBV yields 3.06%● Live data
📍 MAOIF pulled ahead of the other in Year 1
Combined, MAOIF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MAOIF + ABBV for your $10,000?
Manitou BF SA develops, manufactures, and provides equipment and services for the construction, agriculture, and industry sectors worldwide. It operates in two divisions, Product, and Services & Solutions. The company offers material handling, access, and earthmoving equipment, including rough-terrain fixed, rotating, and heavy-duty telehandlers; rough-terrain, semi-industrial, and industrial forklift trucks; wheeled or tracked skid-steer, articulated, and backhoe loaders; aerial work platforms; and truck-mounted forklifts, as well as warehousing equipment and attachments. It also provides attachments, such as buckets, clamps, fork handling solutions, forks and grapples, jibs, work platforms, skips, sweepers and cleaners, winches, mining accessories, and miscellaneous attachments, as well as backrest, carriage, and interface references. In addition, the company offers value added services comprising technical training, new or refurbished spare parts, after-sales service, machine connectivity, financing solutions, maintenance and warranty extension contracts, rent-to-rent leases, full-service contracts, recovery, repair, and resale of used equipment. The company offers its products through a network of dealers under the Manitou, Gehl, and Mustang by Manitou brands. Manitou BF SA was incorporated in 1954 and is headquartered in Ancenis, France.
Full MAOIF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.